ERK3 promotes migration and invasion and tumorigenesis of lung cancer cells expressing either wild-type KRAS (e.g., H1299) or mutants (e.g., A549 and H23) (Long et al., 2012; Bogucka et al., 2021; Cai et al., 2021). Here, MAPK6 is linked to lung carcinoma.